10x Genomics, Inc. (TXG)

Health Services • Health Care

Stock AI

News & Reports

July 29, 2026 10x Genomics Partners with Lausanne University Hospital to Enhance Cancer Diagnostics 10x Genomics has partnered with Lausanne University Hospital to advance cancer diagnostics through innovative single-cell and spatial technologies. This collaboration aims to identify actionable biomarkers for improved treatment decisions, addressing the complexities of modern oncology.

July 15, 2026 10x Genomics Set to Unveil Q2 2026 Financial Results: A Look Ahead 10x Genomics will announce its Q2 2026 financial results on August 6, 2026, followed by a conference call for investors. The company continues to innovate in life sciences, impacting research and health.

June 17, 2026 10x Genomics Partners with Cleveland Clinic to Enhance Bladder Cancer Diagnostics 10x Genomics has partnered with Cleveland Clinic to improve bladder cancer diagnostics through advanced single cell and spatial technologies. This multi-year initiative aims to identify biomarkers that predict treatment responses, ultimately enhancing patient outcomes in oncology.

June 09, 2026 10x Genomics Expands Proteomics Capabilities through Strategic Acquisition of Proteintech Genomics 10x Genomics has acquired Proteintech Genomics to enhance its proteomics capabilities, focusing on high-plex solutions for single-cell and spatial applications. This strategic move aims to integrate transcriptomic and proteomic data, advancing biological research and innovation.

May 07, 2026 10x Genomics Reports First Quarter 2026 Financial Results 10x Genomics reported Q1 2026 financial results with a 3% revenue decrease to $150.8 million. The launch of Atera and a partnership with Bioptimus signal growth potential. The company maintains a strong financial position with $539.8 million in cash equivalents.

April 29, 2026 10x Genomics to Showcase Innovations at BofA Securities 2026 Healthcare Conference 10x Genomics will showcase its innovations at the BofA Securities 2026 Healthcare Conference, featuring a fireside chat with management. The event aims to provide insights into the company's advancements in life sciences and their impact on healthcare research.

April 19, 2026 10x Genomics Unveils Atera: A Game-Changer in Spatial Biology 10x Genomics has launched Atera, a revolutionary platform for spatial biology that offers whole-transcriptome analysis with single-cell sensitivity. This innovation addresses the limitations of traditional methods and is poised to significantly advance cancer research and our understanding of biological systems.

April 15, 2026 10x Genomics to Announce First Quarter 2026 Financial Results 10x Genomics is set to announce its Q1 2026 financial results on May 7, 2026, followed by a conference call for investors. The company continues to lead in life sciences technology, focusing on single cell and spatial biology innovations.

February 19, 2026 10x Genomics to Engage in Fireside Chat at TD Cowen Health Care Conference 10x Genomics will participate in a fireside chat at the TD Cowen Health Care Conference on March 3, 2026. The session will cover the company's advancements in single cell and spatial biology, aimed at enhancing investor understanding and engagement.

February 13, 2026 10x Genomics, Inc. Delivers Mixed Results in 2025 Annual Report: A Year of Challenges and Strategic Growth 10x Genomics' 2025 annual report reveals a 2% revenue decline driven by lower instrument sales, offset by increased consumable and license revenue. Despite a net loss, strategic acquisitions signal potential for future growth.

February 12, 2026 10x Genomics Reports Financial Results for Q4 and Full Year 2025 10x Genomics reported a revenue increase for Q4 2025, showcasing improvements in gross margin and reduced net loss. The company also announced strategic partnerships aimed at enhancing research capabilities and set a cautious revenue guidance for 2026.

February 04, 2026 10x Genomics Partners with PharosAI to Revolutionize Cancer Research 10x Genomics has partnered with PharosAI to create extensive cancer datasets using AI and spatial biology, aiming to enhance cancer research and improve patient care. The initiative will focus initially on breast cancer, leveraging advanced technology to democratize access to vital data for researchers.

January 22, 2026 10x Genomics Set to Unveil Q4 and Full Year 2025 Financial Results 10x Genomics is set to release its Q4 and full year 2025 financial results on February 12, 2026. A conference call will follow to discuss the outcomes and future outlook, highlighting the company's advancements in life sciences.

January 12, 2026 10x Genomics Partners with Brigham & Women's Hospital to Enhance Blood-Based Diagnostics for Autoimmune Diseases 10x Genomics partners with Brigham & Women's Hospital to study blood samples from autoimmune disease patients. This collaboration aims to uncover immune signatures that improve diagnostics and treatment strategies for conditions like rheumatoid arthritis and lupus.

January 12, 2026 10x Genomics Partners with Dana-Farber to Pioneering Tumor Analysis 10x Genomics has partnered with Dana-Farber Cancer Institute to enhance cancer treatment through advanced tumor analysis. This collaboration aims to decode treatment responses and resistance mechanisms, paving the way for personalized therapies. Key technologies employed include single cell assays and spatial profiling to improve patient outcomes.

January 12, 2026 10x Genomics Powers New AI-Driven Initiative in Immuno-Oncology 10x Genomics has partnered with the Cancer Research Institute to launch an AI-driven initiative in immuno-oncology. This collaboration aims to enhance cancer treatment by leveraging advanced genomic tools and AI technology to analyze complex data and identify new therapeutic targets.

January 11, 2026 10x Genomics Reports Preliminary Financial Results for Q4 and Full Year 2025 10x Genomics reported Q4 2025 revenue of $166M, showing mixed results with growth in consumables but declines in instruments. The company’s strong balance sheet positions it well for future growth amidst market challenges.

December 29, 2025 10x Genomics to Showcase Innovations at the 44th Annual J.P. Morgan Healthcare Conference 10x Genomics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, showcasing their latest advancements in single-cell and spatial biology technologies. The event will include a live webcast, allowing global access to insights into their innovative research solutions.

November 18, 2025 10x Genomics Fuels Groundbreaking Pan-Cancer Spatial Atlas Initiative 10x Genomics has launched the ASTRA initiative in collaboration with leading research institutions to create a pan-cancer spatial atlas. This project aims to enhance cancer research and address regional disparities by mapping immune interactions across diverse tumor samples in the Asia-Pacific.

November 11, 2025 10x Genomics to Showcase Innovations at Wolfe Research Healthcare Conference 2025 10x Genomics will participate in the Wolfe Research Healthcare Conference on November 18, featuring a fireside chat about their innovations in single-cell biology. A live webcast will be available for those interested in the latest developments in healthcare technology.

November 07, 2025 10x Genomics Reports Q3 2025: A Mixed Bag of Losses and Strategic Expansion 10x Genomics' Q3 2025 results show a net loss of $27.5 million amid strategic acquisitions and a decline in instrument revenue. However, legal settlements and cost management initiatives provide a hopeful outlook for future growth in the life sciences sector.

November 06, 2025 10x Genomics Reports Third Quarter 2025 Financial Results 10x Genomics reported mixed financial results for Q3 2025, with revenues at $149 million and narrowed losses. Innovations like Chromium Flex and Xenium Protein signal potential growth despite market challenges.

October 29, 2025 10x Genomics Launches Next-Generation Chromium Flex: A Leap Forward in Single Cell Research 10x Genomics has launched its next-generation Chromium Flex assay, enhancing single cell research with improved scalability and cost efficiency. This innovative technology allows profiling of up to 384 samples and 100 million cells weekly, empowering researchers to gain deeper biological insights.

October 20, 2025 10x Genomics Partners with Anthropic to Revolutionize Life Sciences Analysis 10x Genomics partners with Anthropic to enhance life sciences analysis through AI. This collaboration allows scientists to engage with complex data using plain English, simplifying research processes and accelerating discoveries.

October 09, 2025 10x Genomics Set to Report Q3 2025 Financial Results 10x Genomics is set to announce its Q3 2025 financial results on November 6, 2025. A public conference call will follow to discuss the results and future strategies, providing key insights for investors and analysts.

September 09, 2025 10x Genomics Partners with CLISEQ and Weizmann Institute for Innovative Hematology Study The PERIBLOOD trial, a collaboration between CLISEQ, 10x Genomics, and the Weizmann Institute, seeks to evaluate single-cell RNA sequencing as a non-invasive alternative to bone marrow aspiration for diagnosing blood disorders. This groundbreaking study could revolutionize diagnostics and improve patient outcomes in hematology.

August 27, 2025 10x Genomics Set to Shine at Morgan Stanley Healthcare Conference 10x Genomics will participate in the Morgan Stanley Global Healthcare Conference, sharing insights on their innovative technologies in a fireside chat. Stakeholders can access the discussion via live webcast. The company continues to lead in life sciences, enhancing research in critical health areas.

August 19, 2025 10x Genomics Unveils Xenium Protein, Paving the Path for Advanced Spatial Biology 10x Genomics has launched the Xenium Protein, a groundbreaking tool that allows simultaneous RNA and protein analysis within the same sample. This innovation is set to streamline research workflows and enhance the accuracy of multiomic studies, paving the way for significant advancements in understanding complex diseases.

August 08, 2025 10x Genomics Reports a Transformative Q2 2025 In its Q2 2025 report, 10x Genomics reveals a significant turnaround with a net income of $34.5 million, contrasting last year's losses. Despite a revenue decline, strategic settlements and effective cost reduction strategies have improved their financial outlook.

August 07, 2025 10x Genomics Expands Horizons with Acquisition of Scale Biosciences 10x Genomics has acquired Scale Biosciences to strengthen its single cell analysis capabilities. This move aims to make single cell technologies more accessible and scalable, enhancing research potential and innovation in biological discovery.

August 07, 2025 10x Genomics Reports Strong Second Quarter Results Amid Strategic Acquisitions 10x Genomics showcased resilience with $172.9 million in Q2 revenue, driven by strategic acquisitions and product innovations. The company reported a significant increase in net income and improved profitability metrics, positioning itself for future growth despite market challenges.

July 17, 2025 10x Genomics Partners with A*STAR GIS for Innovative TISHUMAP Study 10x Genomics partners with A*STAR GIS on the TISHUMAP project to enhance drug target discovery for cancer and inflammatory diseases. Utilizing the Xenium platform and AI, they aim to improve diagnostic tools and personalized treatment strategies.

July 10, 2025 10x Genomics Set to Announce Q2 2025 Financial Results 10x Genomics will release its Q2 2025 financial results on August 7, 2025, after market close, followed by a conference call to discuss the outcomes. The report is anticipated to shed light on the company's performance amid ongoing developments in biotech.

May 14, 2025 10x Genomics Settles Patent Litigation with Bruker for $68 Million 10x Genomics has reached a $68 million settlement with Bruker, resolving all patent litigation globally. This agreement will support 10x's revenue and innovation in the life sciences sector.

May 09, 2025 10x Genomics Reports Q1 2025 Results: A Mixed Bag Amid Strategic Shift 10x Genomics reported mixed Q1 2025 results, with a 2% decline in revenue and a net loss of $34.4 million. Despite challenges, the company shows resilience through increased consumables sales and strategic maneuvers.

May 08, 2025 10x Genomics Reports First Quarter 2025 Financial Results 10x Genomics has released its financial results for Q1 2025, showing a revenue of $154.9 million, impacted by a decline in instrument sales. The company is implementing cost-saving measures and exploring new product launches to navigate financial challenges and enhance growth.

April 30, 2025 10x Genomics to Showcase Innovations at BofA Securities 2025 Healthcare Conference 10x Genomics will showcase its cutting-edge technologies at the BofA Securities 2025 Healthcare Conference on May 13. The event includes a fireside chat with management to discuss their contributions to life sciences and ongoing innovations. This is a key opportunity for investors to engage with the company's strategic direction.

April 14, 2025 10x Genomics Set to Reveal Q1 2025 Financial Results 10x Genomics is set to release its Q1 2025 financial results on May 8, followed by a conference call to discuss the outcomes and future outlook. The company continues to lead in innovative life sciences solutions, crucial for advancing biological research.

February 23, 2025 10x Genomics Unveils Innovation Roadmap at AGBT General Meeting At the AGBT General Meeting, 10x Genomics unveiled groundbreaking innovations in single cell and spatial biology, aimed at improving research efficiency and data insights. Key advancements include new workflows for sample analysis and enhancements to their Visium and Xenium platforms, reaffirming their leadership in the field.

February 18, 2025 10x Genomics to Showcase Innovations at Upcoming Health Care Conference 10x Genomics will showcase its advancements at the 45th Annual TD Cowen Health Care Conference on March 4. The event includes a live webcast for insights into their innovations in life sciences.

February 13, 2025 10x Genomics, Inc. Reports 2024 Financial Performance: A Year of Mixed Results and Strategic Growth 10x Genomics' 2024 report highlights a decline in instrument sales but significant growth in spatial products revenue. With net losses improving, the company focuses on R&D investments and strategic pricing to drive future growth despite ongoing market challenges.

February 12, 2025 10x Genomics Reports Financial Results for Q4 and Full Year 2024, Outlines 2025 Outlook 10x Genomics reported a revenue decline in Q4 2024 but improved gross margins and reduced operating losses. The company launched the Billion Cells Project and anticipates slight revenue growth in 2025, reflecting confidence in future opportunities.

February 09, 2025 SWOT Analysis of 10x Genomics, Inc. in 2025 This article provides a detailed SWOT analysis of 10x Genomics, Inc., examining its strengths in innovative technology and market position, while addressing weaknesses such as net losses and product dependency. The analysis also identifies growth opportunities in the expanding life sciences market and outlines potential threats from competition and regulatory risks.

October 29, 2024 10x Genomics Reports Mixed Results in Q3 2024: A Dive into Financial Performance 10x Genomics reported a 1% revenue decline in Q3 2024, driven by a significant drop in instrument sales, while consumables showed growth. Despite losses, operating expenses decreased, indicating improved cost management and a focus on product innovation.

August 08, 2024 10x Genomics Reports Steady Growth in Q2 2024 10x Genomics has reported a 4% revenue increase for Q2 2024, reaching $153.1 million. Despite a net loss, significant cost management and liquidity improvements position the company well for future growth.

April 30, 2024 10x Genomics Reports Mixed Results in Q1 2024 Financials 10x Genomics' Q1 2024 financial results show a 5% revenue increase to $141 million, driven by a surge in instrument sales. However, the net loss grew to $59.94 million, reflecting rising costs and operational challenges as the company navigates a dynamic life sciences market.

10x Genomics Set to Announce Q2 2025 Financial Results

Last updated: July 10, 2025 •

Taurigo

1. Anticipation Builds for Upcoming Financial Report

10x Genomics, Inc. (Nasdaq: TXG), a prominent player in the field of single cell and spatial biology, has announced a date for its financial results for the second quarter ending June 30, 2025. Investors and analysts alike are gearing up for the report, which is scheduled to be released after market close on Thursday, August 7, 2025.

The upcoming financial results will provide crucial insights into the company's performance and operational developments during the quarter, which is particularly significant given the ongoing evolution in the biotech and life sciences sectors.

2. Conference Call and Webcast Details

Following the release of the financial results, 10x Genomics will host a public conference call and live webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. This forum will allow company executives to discuss the quarterly results in detail, share business developments, and provide an outlook for the future.

Investors and interested parties can access the live audio of the webcast in the "Investors" section on the company’s website. For those unable to attend the live session, an archived version of the webcast will be available for replay for at least 45 days following the event.

3. About 10x Genomics

Founded with the mission to advance human health through innovative technology, 10x Genomics is dedicated to providing researchers with powerful tools to explore biological systems at unprecedented resolutions. The company's integrated research solutions encompass instruments, consumables, and software specifically designed for single cell and spatial biology.

These innovations have already facilitated breakthroughs across various fields, including oncology, immunology, and neuroscience. By enabling researchers to unravel the complexities of biology, 10x Genomics is at the forefront of transforming our understanding of health and disease.

4. Navigating Disclosure Responsibilities

10x Genomics emphasizes its commitment to transparent communication with stakeholders. The company utilizes various channels, including filings with the Securities and Exchange Commission, press releases, public conference calls, and social media platforms, to disclose material non-public information and adhere to its disclosure obligations.

As the date for the financial results approaches, the anticipation surrounding 10x Genomics' performance continues to grow. Investors will be keenly watching for indicators of the company’s growth trajectory and strategic direction in an increasingly competitive landscape.

For those interested in following the company’s journey, more information can be found on their official website or through their various social media channels.

Original press release

You may also be interested in: